Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 202

1.

GSTΠ stimulates caveolin-1-regulated polyamine uptake via actin remodeling.

Uemura T, Tsaprailis G, Gerner EW.

Oncotarget. 2019 Oct 1;10(55):5713-5723. doi: 10.18632/oncotarget.27192. eCollection 2019 Oct 1.

2.

Cancer pharmacoprevention: Targeting polyamine metabolism to manage risk factors for colon cancer.

Gerner EW, Bruckheimer E, Cohen A.

J Biol Chem. 2018 Nov 30;293(48):18770-18778. doi: 10.1074/jbc.TM118.003343. Epub 2018 Oct 24. Review.

PMID:
30355737
3.

Intermittent Dosing with Sulindac Provides Effective Colorectal Cancer Chemoprevention in the Azoxymethane-Treated Mouse Model.

Chandra S, Nymeyer AC, Rice PF, Gerner EW, Barton JK.

Cancer Prev Res (Phila). 2017 Aug;10(8):459-466. doi: 10.1158/1940-6207.CAPR-17-0038. Epub 2017 Jun 13.

4.

Time-serial Assessment of Drug Combination Interventions in a Mouse Model of Colorectal Carcinogenesis Using Optical Coherence Tomography.

LeGendre-McGhee S, Rice PS, Wall RA, Sprute KJ, Bommireddy R, Luttman AM, Nagle RB, Abril ER, Farrell K, Hsu CH, Roe DJ, Gerner EW, Ignatenko NA, Barton JK.

Cancer Growth Metastasis. 2015 Sep 7;8(Suppl 1):63-80. doi: 10.4137/CGM.S21216. eCollection 2015.

5.

A Phase I Trial of DFMO Targeting Polyamine Addiction in Patients with Relapsed/Refractory Neuroblastoma.

Saulnier Sholler GL, Gerner EW, Bergendahl G, MacArthur RB, VanderWerff A, Ashikaga T, Bond JP, Ferguson W, Roberts W, Wada RK, Eslin D, Kraveka JM, Kaplan J, Mitchell D, Parikh NS, Neville K, Sender L, Higgins T, Kawakita M, Hiramatsu K, Moriya SS, Bachmann AS.

PLoS One. 2015 May 27;10(5):e0127246. doi: 10.1371/journal.pone.0127246. eCollection 2015.

6.

Combined benefit of prediction and treatment: a criterion for evaluating clinical prediction models.

Billheimer D, Gerner EW, McLaren CE, LaFleur B.

Cancer Inform. 2014 Oct 5;13(Suppl 2):93-103. doi: 10.4137/CIN.S13780. eCollection 2014.

7.

Dietary polyamine intake and polyamines measured in urine.

Vargas AJ, Ashbeck EL, Thomson CA, Gerner EW, Thompson PA.

Nutr Cancer. 2014;66(7):1144-53. doi: 10.1080/01635581.2014.949801. Epub 2014 Sep 10.

PMID:
25204413
8.

Chemoprevention of prostate cancer with the polyamine synthesis inhibitor difluoromethylornithine.

Meyskens FL Jr, Simoneau AR, Gerner EW.

Recent Results Cancer Res. 2014;202:115-20. doi: 10.1007/978-3-642-45195-9_14.

PMID:
24531785
9.

Polyamines are oncometabolites that regulate the LIN28/let-7 pathway in colorectal cancer cells.

Paz EA, LaFleur B, Gerner EW.

Mol Carcinog. 2014 Feb;53 Suppl 1:E96-106. doi: 10.1002/mc.22051. Epub 2013 Jun 4.

PMID:
23737330
10.

Extracellular DNA in pancreatic cancer promotes cell invasion and metastasis.

Wen F, Shen A, Choi A, Gerner EW, Shi J.

Cancer Res. 2013 Jul 15;73(14):4256-66. doi: 10.1158/0008-5472.CAN-12-3287. Epub 2013 May 30.

11.

Get the fat out!

Ignatenko NA, Gerner EW.

Cancer Prev Res (Phila). 2013 Mar;6(3):161-4. doi: 10.1158/1940-6207.CAPR-13-0025.

12.

Role of dietary polyamines in a phase III clinical trial of difluoromethylornithine (DFMO) and sulindac for prevention of sporadic colorectal adenomas.

Raj KP, Zell JA, Rock CL, McLaren CE, Zoumas-Morse C, Gerner EW, Meyskens FL.

Br J Cancer. 2013 Feb 19;108(3):512-8. doi: 10.1038/bjc.2013.15. Epub 2013 Jan 22.

13.

Caveolin-1 is a novel regulator of K-RAS-dependent migration in colon carcinogenesis.

Basu Roy UK, Henkhaus RS, Loupakis F, Cremolini C, Gerner EW, Ignatenko NA.

Int J Cancer. 2013 Jul;133(1):43-57. doi: 10.1002/ijc.28001. Epub 2013 Feb 12. Erratum in: Int J Cancer. 2015 Oct 15;137(8):E18.

14.

Clinical end points for developing pharmaceuticals to manage patients with a sporadic or genetic risk of colorectal cancer.

Rial NS, Zell JA, Cohen AM, Gerner EW.

Expert Rev Gastroenterol Hepatol. 2012 Aug;6(4):507-17. doi: 10.1586/egh.12.23. Review.

15.

Role of obesity in a randomized placebo-controlled trial of difluoromethylornithine (DFMO) + sulindac for the prevention of sporadic colorectal adenomas.

Zell JA, Lin BS, Madson N, McLaren CE, Gerner EW, Meyskens FL.

Cancer Causes Control. 2012 Oct;23(10):1739-44. doi: 10.1007/s10552-012-0051-6. Epub 2012 Aug 21.

16.

Dietary polyamine intake and risk of colorectal adenomatous polyps.

Vargas AJ, Wertheim BC, Gerner EW, Thomson CA, Rock CL, Thompson PA.

Am J Clin Nutr. 2012 Jul;96(1):133-41. doi: 10.3945/ajcn.111.030353. Epub 2012 May 30.

17.

Chemoprevention in patients with genetic risk of colorectal cancers.

Laukaitis CM, Erdman SH, Gerner EW.

Colorectal Cancer. 2012;1(3):225-240.

18.

DFMO: targeted risk reduction therapy for colorectal neoplasia.

Laukaitis CM, Gerner EW.

Best Pract Res Clin Gastroenterol. 2011 Aug;25(4-5):495-506. doi: 10.1016/j.bpg.2011.09.007. Review.

19.

Defining the role of polyamines in colon carcinogenesis using mouse models.

Ignatenko NA, Gerner EW, Besselsen DG.

J Carcinog. 2011;10:10. doi: 10.4103/1477-3163.79673. Epub 2011 Apr 16.

20.

Back to the future: mechanism-based, mutation-specific combination chemoprevention with a synthetic lethality approach.

Meyskens FL Jr, Gerner EW.

Cancer Prev Res (Phila). 2011 May;4(5):628-32. doi: 10.1158/1940-6207.CAPR-11-0162.

21.

Of timing and surrogates: a way forward for cancer chemoprevention.

Thompson PA, Gerner EW.

Clin Cancer Res. 2011 Jun 1;17(11):3509-11. doi: 10.1158/1078-0432.CCR-11-0643. Epub 2011 Apr 15.

22.

Polyamine transport systems in mammalian cells and tissues.

Uemura T, Gerner EW.

Methods Mol Biol. 2011;720:339-48. doi: 10.1007/978-1-61779-034-8_21.

23.

Targeting polyamines and inflammation for cancer prevention.

Babbar N, Gerner EW.

Recent Results Cancer Res. 2011;188:49-64. doi: 10.1007/978-3-642-10858-7_4. Review.

24.

Ornithine decarboxylase-1 polymorphism, chemoprevention with eflornithine and sulindac, and outcomes among colorectal adenoma patients.

Zell JA, McLaren CE, Chen WP, Thompson PA, Gerner EW, Meyskens FL.

J Natl Cancer Inst. 2010 Oct 6;102(19):1513-6. doi: 10.1093/jnci/djq325. Epub 2010 Aug 26.

25.

Levels of rectal mucosal polyamines and prostaglandin E2 predict ability of DFMO and sulindac to prevent colorectal adenoma.

Thompson PA, Wertheim BC, Zell JA, Chen WP, McLaren CE, LaFleur BJ, Meyskens FL, Gerner EW.

Gastroenterology. 2010 Sep;139(3):797-805, 805.e1. doi: 10.1053/j.gastro.2010.06.005. Epub 2010 Jun 9.

26.

Polyamine transport is mediated by both endocytic and solute carrier transport mechanisms in the gastrointestinal tract.

Uemura T, Stringer DE, Blohm-Mangone KA, Gerner EW.

Am J Physiol Gastrointest Liver Physiol. 2010 Aug;299(2):G517-22. doi: 10.1152/ajpgi.00169.2010. Epub 2010 Jun 3.

27.

Cancer chemoprevention locks onto a new polyamine metabolic target.

Gerner EW.

Cancer Prev Res (Phila). 2010 Feb;3(2):125-7. doi: 10.1158/1940-6207.CAPR-09-0252. Epub 2010 Jan 26. Review.

28.

Polyamines as mediators of APC-dependent intestinal carcinogenesis and cancer chemoprevention.

Rial NS, Meyskens FL, Gerner EW.

Essays Biochem. 2009 Nov 4;46:111-24. doi: 10.1042/bse0460008. Review.

29.

Vitamin D receptor ligands, adenomatous polyposis coli, and the vitamin D receptor FokI polymorphism collectively modulate beta-catenin activity in colon cancer cells.

Egan JB, Thompson PA, Vitanov MV, Bartik L, Jacobs ET, Haussler MR, Gerner EW, Jurutka PW.

Mol Carcinog. 2010 Apr;49(4):337-52. doi: 10.1002/mc.20603.

30.

Associations of a polymorphism in the ornithine decarboxylase gene with colorectal cancer survival.

Zell JA, Ziogas A, Ignatenko N, Honda J, Qu N, Bobbs AS, Neuhausen SL, Gerner EW, Anton-Culver H.

Clin Cancer Res. 2009 Oct 1;15(19):6208-16. doi: 10.1158/1078-0432.CCR-09-0592. Epub 2009 Sep 29.

31.

Current concepts in colorectal cancer prevention.

Thompson PA, Gerner EW.

Expert Rev Gastroenterol Hepatol. 2009 Aug;3(4):369-82. doi: 10.1586/egh.09.28. Review.

32.

Gene expression analysis of HCT116 colon tumor-derived cells treated with the polyamine analog PG-11047.

Ignatenko NA, Yerushalmi HF, Pandey R, Kachel KL, Stringer DE, Marton LJ, Gerner EW.

Cancer Genomics Proteomics. 2009 May-Jun;6(3):161-75.

33.

Components of metabolic syndrome and metachronous colorectal neoplasia.

Ashbeck EL, Jacobs ET, Martínez ME, Gerner EW, Lance P, Thompson PA.

Cancer Epidemiol Biomarkers Prev. 2009 Apr;18(4):1134-43. doi: 10.1158/1055-9965.EPI-08-1015. Epub 2009 Mar 24.

34.

Risk of cardiovascular events in a randomized placebo-controlled, double-blind trial of difluoromethylornithine plus sulindac for the prevention of sporadic colorectal adenomas.

Zell JA, Pelot D, Chen WP, McLaren CE, Gerner EW, Meyskens FL.

Cancer Prev Res (Phila). 2009 Mar;2(3):209-12. doi: 10.1158/1940-6207.CAPR-08-0203. Epub 2009 Mar 3.

35.

Combination chemoprevention for colon cancer targeting polyamine synthesis and inflammation.

Gerner EW, Meyskens FL Jr.

Clin Cancer Res. 2009 Feb 1;15(3):758-61. doi: 10.1158/1078-0432.CCR-08-2235. Review.

36.

Regulation of deoxycholate induction of CXCL8 by the adenomatous polyposis coli gene in colorectal cancer.

Rial NS, Lazennec G, Prasad AR, Krouse RS, Lance P, Gerner EW.

Int J Cancer. 2009 May 15;124(10):2270-80. doi: 10.1002/ijc.24226.

37.

Longitudinal assessment of air conduction audiograms in a phase III clinical trial of difluoromethylornithine and sulindac for prevention of sporadic colorectal adenomas.

McLaren CE, Fujikawa-Brooks S, Chen WP, Gillen DL, Pelot D, Gerner EW, Meyskens FL Jr.

Cancer Prev Res (Phila). 2008 Dec;1(7):514-21. doi: 10.1158/1940-6207.CAPR-08-0074.

38.

The untapped potential of genetically engineered mouse models in chemoprevention research: opportunities and challenges.

Abate-Shen C, Brown PH, Colburn NH, Gerner EW, Green JE, Lipkin M, Nelson WG, Threadgill D.

Cancer Prev Res (Phila). 2008 Aug;1(3):161-6. doi: 10.1158/1940-6207.CAPR-08-0076. Review.

39.

Combination chemoprevention of intestinal carcinogenesis in a murine model of familial adenomatous polyposis.

Ignatenko NA, Besselsen DG, Stringer DE, Blohm-Mangone KA, Cui H, Gerner EW.

Nutr Cancer. 2008;60 Suppl 1:30-5. doi: 10.1080/01635580802401317.

PMID:
19003578
40.

Difluoromethylornithine plus sulindac for the prevention of sporadic colorectal adenomas: a randomized placebo-controlled, double-blind trial.

Meyskens FL Jr, McLaren CE, Pelot D, Fujikawa-Brooks S, Carpenter PM, Hawk E, Kelloff G, Lawson MJ, Kidao J, McCracken J, Albers CG, Ahnen DJ, Turgeon DK, Goldschmid S, Lance P, Hagedorn CH, Gillen DL, Gerner EW.

Cancer Prev Res (Phila). 2008 Jun;1(1):32-8. doi: 10.1158/1940-6207.CAPR-08-0042.

41.

Identification and characterization of a diamine exporter in colon epithelial cells.

Uemura T, Yerushalmi HF, Tsaprailis G, Stringer DE, Pastorian KE, Hawel L 3rd, Byus CV, Gerner EW.

J Biol Chem. 2008 Sep 26;283(39):26428-35. doi: 10.1074/jbc.M804714200. Epub 2008 Jul 25.

42.

Presence of a TA haplotype in the APC gene containing the common 1822 polymorphism and colorectal adenoma.

Egan JB, Jacobs ET, Martínez ME, Gerner EW, Jurutka PW, Thompson PA.

Cancer Res. 2008 Jul 15;68(14):6006-13. doi: 10.1158/0008-5472.CAN-08-1084.

43.

Kallikrein 6 is a mediator of K-RAS-dependent migration of colon carcinoma cells.

Henkhaus RS, Gerner EW, Ignatenko NA.

Biol Chem. 2008 Jun;389(6):757-64. doi: 10.1515/BC.2008.087.

44.

Wild-type APC regulates caveolin-1 expression in human colon adenocarcinoma cell lines via FOXO1a and C-myc.

Roy UK, Henkhaus RS, Ignatenko NA, Mora J, Fultz KE, Gerner EW.

Mol Carcinog. 2008 Dec;47(12):947-55. doi: 10.1002/mc.20451.

45.

HuRrying colon cancer progression.

Ignatenko NA, Gerner EW.

Cancer Biol Ther. 2008 Mar;7(3):428-9. Epub 2007 Feb 2. No abstract available.

46.

Caveolin-1-mediated expression and secretion of kallikrein 6 in colon cancer cells.

Henkhaus RS, Roy UK, Cavallo-Medved D, Sloane BF, Gerner EW, Ignatenko NA.

Neoplasia. 2008 Feb;10(2):140-8.

47.

The effect of difluoromethylornithine on decreasing prostate size and polyamines in men: results of a year-long phase IIb randomized placebo-controlled chemoprevention trial.

Simoneau AR, Gerner EW, Nagle R, Ziogas A, Fujikawa-Brooks S, Yerushalmi H, Ahlering TE, Lieberman R, McLaren CE, Anton-Culver H, Meyskens FL Jr.

Cancer Epidemiol Biomarkers Prev. 2008 Feb;17(2):292-9. doi: 10.1158/1055-9965.EPI-07-0658.

48.

Activated K-RAS increases polyamine uptake in human colon cancer cells through modulation of caveolar endocytosis.

Roy UK, Rial NS, Kachel KL, Gerner EW.

Mol Carcinog. 2008 Jul;47(7):538-53. doi: 10.1002/mc.20414.

49.

Serial endoscopy in azoxymethane treated mice using ultra-high resolution optical coherence tomography.

Hariri LP, Qiu Z, Tumlinson AR, Besselsen DG, Gerner EW, Ignatenko NA, Povazay B, Hermann B, Sattmann H, McNally J, Unterhuber A, Drexler W, Barton JK.

Cancer Biol Ther. 2007 Nov;6(11):1753-62. Epub 2007 Aug 12.

PMID:
17986850
50.

Activation of polyamine catabolism by N1, N11-diethylnorspermine alters the cellular localization of mTOR and downregulates mTOR protein level in glioblastoma cells.

Jiang R, Choi W, Hu L, Gerner EW, Hamilton SR, Zhang W.

Cancer Biol Ther. 2007 Oct;6(10):1644-8. Epub 2007 Jul 27.

PMID:
17921698

Supplemental Content

Loading ...
Support Center